Prognostic value of routinely available data in patients with stable coronary heart disease. A 10-year follow-up of patients sampled at random times during their disease course

Open Heart
Per WinkelChristian Gluud

Abstract

To characterise the long-term prognosis of patients with stable coronary artery heart disease by means of 'standard predictors' defined as demographic, clinical and biochemical quantities routinely available in general practices and ascertained at an interview not prompted by renewed cardiac complaints. This is an observational study based on data from 2199 Copenhagen placebo patients from the 'clarithromycin for patients with stable coronary heart disease' trial of patients with stable coronary heart disease. In the trial, we compared the effects of 14 days of clarithromycin treatment versus placebo. The predictors were based on the interview forms and blood samples collected at entry, along with demographic information from hospital files.We studied 'standard predictors' of a composite outcome (myocardial infarction, unstable angina, cerebrovascular disease or all-cause death) and of all-cause death. Using Cox regression, we compared predictions of status at 3, 6 and 9 years without and with the use of 'standard predictors' and used receiver operating characteristic statistic. Few 'standard predictors' were associated (p<0.01) with the composite outcome or with all-cause death. When no 'standard predictors' were included, 63....Continue Reading

References

Feb 13, 2001·The American Journal of Cardiology·A HoffmeisterW Koenig
Sep 28, 2005·International Journal of Cardiology·Takeshi YamamotoTeruo Takano
Nov 27, 2010·Scandinavian Journal of Clinical and Laboratory Investigation·Marina J HarutyunyanUNKNOWN CLARICOR Trial Group
Dec 16, 2010·Biometrics·R M Pfeiffer, M H Gail
Feb 24, 2011·JAMA : the Journal of the American Medical Association·Issa J Dahabreh, David M Kent
Aug 4, 2011·Scandinavian Journal of Public Health·Karin Helweg-Larsen
Aug 4, 2011·Scandinavian Journal of Public Health·Elsebeth LyngeMatejka Rebolj
Jan 20, 2012·Journal of Clinical Epidemiology·Erik KjollerUNKNOWN CLARICOR Trial Group
Jul 6, 2012·The New England Journal of Medicine·Lesley A InkerUNKNOWN CKD-EPI Investigators
Dec 22, 2012·Journal of Clinical Epidemiology·Luc J M SmitsSimone J S Sep
Jul 16, 2014·Scandinavian Journal of Clinical and Laboratory Investigation·Mette BjerreUNKNOWN Claricor Trial Group
Jul 30, 2014·American Heart Journal·Erik KjøllerUNKNOWN CLARICOR Trial Group
Aug 12, 2014·JAMA Internal Medicine·Philippe Gabriel StegUNKNOWN Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease (CLARIFY) Investigators
Jun 30, 2015·Journal of Clinical Epidemiology·William CampbellA Cecile J W Janssens
Sep 14, 2016·Maturitas·Johanna Helmersson-KarlqvistAnders Larsson
Aug 5, 2017·European Heart Journal. Acute Cardiovascular Care·Stuart J PocockHéctor Bueno

❮ Previous
Next ❯

Methods Mentioned

BETA
percutaneous transluminal coronary angioplasty

Software Mentioned

SAS
CLARICOR

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.